ArticleSmall (Weinheim an der Bergstrasse, Germany)2025
Novabeads: Stimuli-Responsive Signal-Amplifying Hydrogel Microparticles for Enzymeless Fluorescence-Based Detection of microRNA Biomarkers.
Article in Small (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Engineered polymerase-mediated efficient synthesis of site-specifically functionalized RNA and 2'-modified RNA oligonucleotides via genetic alphabet expansion.Nature communications · 2026Article
- Article
- Beyond the 2D Plane: Interfacing Microwave Resonators with Bioreceptor-Functionalized Hydrogel Micropillars for Label-Free Enhanced Sensitivity Biosensing.ACS applied materials & interfaces · 2026Article
- Novabeads: Stimuli-Responsive Signal-Amplifying Hydrogel Microparticles for Enzymeless Fluorescence-Based Detection of microRNA Biomarkers.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Robust and ultrasensitive biosensing platforms for detecting clinically relevant biomarkers from liquid biopsies are vital for precision diagnostics. However, detecting low-abundance biomarkers such as microRNA typically necessitates complex and costly enzyme-based strategies like PCR or isothermal amplification. Here, a materials-driven approach is leveraged to rationally design stimuli-responsive, signal-amplifying, and graphically-encoded hydrogel microparticles, termed Novabeads, for enzyme-free and fluorescence-based biomarker detection. Novabeads incorporate pH-responsive acrylic acid moieties within a polyethylene glycol diacrylate-based network, enabling significant volume reduction (≈5 fold) upon pH modulation. This stimuli-responsive shrinking, coupled with high bioreceptor loading via thiol-ene click chemistry, enables rapid, enzyme-free optical signal amplification. As a proof-of-concept, fluorescently-labeled peptide nucleic acid (PNA) probes are designed for detecting the cancer biomarker miR-16, via a fluorogenic Förster resonance energy transfer (FRET)-based signal. Novabeads exhibit >30 fold signal enhancement over equivalent conventional hydrogel microparticles, driven by three synergistic mechanisms: increased probe loading (≈2.6 fold), enhanced target capture (≈2.8 fold), and shrinkage-driven amplification (≈5 fold), ultimately leading to over 7 fold reduction in detection limit (28.8 pM; 2.9 fmol), and an expanded linear dynamic range. This rationally designed materials-driven biosensing strategy enables next-generation robust, versatile and enzyme-free biosensors for liquid biopsy diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.